Please assess the completion status of the following clinical trial:

Trial Title: HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed breast cancer~* Stage IV~* No prior or not more than one prior chemotherapy for metastatic disease~* Overexpression of HER-2 (3+ on immunohistochemical exam) or amplified genetic expression of c-erbB2/neu (positive by Fish method)~* Performance status 0-2 (ECOG)~Exclusion Criteria:~* Absence of measurable disease~* Life expectancy \< 3 months~* Concomitant malignancy or malignancy within previous 5 years (except basal cell or spinocellular skin cancer and in situ cervical cancer if they have been adequately treated~* Previous treatment with trastuzumab or vinorelbine~* Neutrophils \< 1500/mm3 or platelets \< 100000/mm3 or haemoglobin \< 8 g/dl~* Creatinine \> 1.5 x the value of the upper normal limit~* GOT and/or GPT \> 2.5 x the value of the upper normal limit and/or bilirubin \> 1.5 x the value of the upper normal limit in the absence of liver metastases~* GOT and/or GPT \> 5 x the value of the upper normal limit and/or bilirubin \> 3 x the value of the upper normal limit in the presence of liver metastases~* Left ventricular ejection fraction \< 50% (measured by ultrasound or MUGA angiography)~* Concomitant conditions that contraindicate the use of the drugs in the protocol~* Male gender~* Pregnancy or lactation·~* Incapacity or refusal to provide informed consent~* Inability to comply with followup

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).